Inozyme Pharma, Inc.
INZY · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $58,493 | $173,989 | $330,938 | $273,173 |
| - Cash | $25,846 | $21,081 | $24,575 | $15,233 |
| + Debt | $46,954 | $46,873 | $46,792 | $46,710 |
| Enterprise Value | $79,601 | $199,781 | $353,155 | $304,650 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$26,457 | -$25,475 | -$22,959 | -$25,450 |
| % Margin | – | – | – | – |
| Net Income | -$28,039 | -$27,074 | -$24,570 | -$27,033 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.44 | -0.43 | -0.39 | -0.44 |
| % Growth | -2.3% | -10.3% | 11.4% | – |
| Operating Cash Flow | -$29,149 | -$19,188 | -$24,528 | -$23,658 |
| Capital Expenditures | $0 | -$17 | -$13 | $0 |
| Free Cash Flow | -$29,149 | -$19,205 | -$24,541 | -$23,658 |